GlobeNewswire by notified

4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab

Share

AGC Biologics to produce Procizumab for early and late clinical phases at company’s Chiba and Copenhagen facilities

Seattle, Dec. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) to manufacture and commercialize Procizumab. The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to acute circulatory failure.  

Under the terms of the agreement, the companies will collaborate to transfer and optimize the manufacturing process for Procizumab. AGC Biologics will manufacture the clinical trial materials at its site in Chiba and transfer to its Copenhagen facility for all late phase activities including commercialization, to support early and late clinical phases and launch readiness of 4TEEN4’s monoclonal antibody.

 “We look forward to partnering with 4TEEN4 and working together to develop and manufacture this revolutionary treatment, and help it reach the critical clinical trial phase,” said Patricio Massera, Chief Executive Officer at AGC Biologics. “Our Chiba and Copenhagen sites have the proven experience and expertise to help 4TEEN4 in its journey towards the clinical and market supply of this new innovative therapy.”

4TEEN4 is a preclinical-stage biotech company dedicated to helping critically ill patients suffering from loss of heart function and circulatory shock. Its flagship biologic, Procizumab, is a humanized monoclonal antibody able to inhibit the activity of its target, Dipeptidyl Peptidase 3 (DPP3), stabilize cardiovascular function and potentially increase survival chances e.g., in cardiogenic and septic shock.

“AGC is a high-quality partner with global manufacturing expertise and extensive commercial supply experience, and we are pleased to start a long-standing relationship as we continue to progress in our clinical development,” said Andreas Bergmann, founder and CEO of 4TEEN4. “Preclinical studies of Procizumab in models of cardiovascular failure showed instant efficacy, demonstrating this treatment’s tremendous potential.”

The teams of scientists at AGC Biologics’ Chiba and Copenhagen facilities have more than 20 years’ experience developing and delivering a wide range of mammalian and microbial programs, including several commercially approved products. AGC Biologics also recently announced expansion plans for its facility in Copenhagen that will double the production capacity at the site and meet increasing market demand.

About 4TEEN4 
4TEEN4 is dedicated to improving critically ill patient lives who suffer from hemodynamic instability, end-organ hypoperfusion and multiple organ failure with our first-in-class humanized monoclonal antibody “Procizumab” targeting human dipeptidyl peptidase 3 (DPP3). 4TEEN4 licensed its novel biomarker DPP3 for diagnostic purposes in critical care conditions. 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) was established in 2013 in Hennigsdorf near Berlin, Germany, by Dr. Andreas Bergmann, CEO of 4TEEN4, as part of his Medicine4Future Initiative. For further information, please visit www.4teen4.de

About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

AGC Biologics Contact:
Media Contact: Nick McDonald
nmcdonald@agc.com

4TEEN4 Pharmaceuticals GmbH Contacts:
Investor Contact:
Dr. Karine Bourgeois
Tel: +49(0)1622145536
bourgeois@4teen4.de
Press Contact:
Leen Alsaka Amini
Tel: +49(0)1766 4322 193
amini@4teen4.de

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES19.3.2024 09:30:00 CET | Press release

Bid date, 2024-03-19Auction date2024-03-19Settlement date2024-03-20Maturity Date2024-03-27Nominal amount956 billion SEKInterest rate4.00 %Bid times09.30-10.00 (CET/CEST) on the Bid dateBids are made to phone number08-696 69 70Confirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume956 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term956 billion SEKExpected excess liquidity at full allotment0 billion SEK Stockholm, 2024-03-19

Avance Gas Holding Ltd (AGAS): Successfully completed the sale of our fifth VLGC newbuilding19.3.2024 09:20:18 CET | Press release

Hamilton, Bermuda March 19, 2024 Avance Gas Holding Ltd. («Avance Gas» or «Company») (OSE: AGAS) announce today the successful sale of newbuilding hull 2367 with intended name Avance Castor for a cash consideration of $120 million less broker commission as previously announced in a press release dated December 8, 2023. The Company expect to record a book gain on sale and cash release following repayment of bank financing of $36 million and $61 million respectively. The sale of the sister ship, newbuilding hull 2368 with intended name Avance Pollux, is scheduled to take place in the first half of May 2024. This sale is also expected to result in a book gain and cash release of $36 million and $60 million respectively. For further queries, please contact: Media contact: Øystein Kalleklev, CEO Tel: +47 23 11 40 00 Investor and Analyst contact: Randi Navdal Bekkelund, CFO Tel: +47 23 11 40 00 ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleu

Offentliggørelse af prospekt for Investeringsforeningen Danske Invest19.3.2024 09:00:00 CET | pressemeddelelse

Vi skal herved oplyse, at der er foretaget ændringer i prospektet for Investeringsforeningen Danske Invest. Prospektet for investeringsforeningen Danske Invest er opdateret med lanceringsdato for afdeling Structured Credit – Investment Grade, Accumulating.Derudover er afsnit 6 ”Afdelingernes/andelsklassernes risici” omformuleret bredere til også at omfatte strukturerede gældsinstrumenter for afdeling Structured Credit – Investment Grade, Accumulating. Prospekterne kan fra i dag ses på www.danskeinvest.dk. Med venlig hilsen DANSKE INVEST MANAGEMENT A/S Tina Hjorth Hetting Head of Fund Products

Danske Bank A/S, transactions by persons discharging managerial responsibilities19.3.2024 08:50:12 CET | Press release

19 March 2024 Notification no. 23/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Attachment APMH Invest AS - sale - 2024-03-15

Danske Bank A/S, ledende medarbejderes transaktioner19.3.2024 08:50:12 CET | pressemeddelelse

19. marts 2024 Indberetning nr. 23/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Vedhæftet fil APMH Invest A_S - salg - 2024-03-15

HiddenA line styled icon from Orion Icon Library.Eye